UniProt Q6P3R8 · PDB · AlphaFold · Substrate: MBP · Clone: aa 1-508medium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Avapritinib | 89.7% | 10.3% | 97.73 | 0.644 |
| 2 | Ponatinib | 56.0% | 44.0% | 78.23 | 0.534 |
| 3 | Fostamatinib | 52.8% | 47.2% | 96.74 | 0.613 |
| 4 | Dabrafenib | 39.8% | 60.2% | 94.74 | 0.633 |
| 5 | Pacritinib | 39.0% | 61.0% | 88.64 | 0.452 |
| 6 | Pemigatinib | 35.2% | 64.8% | 98.23 | 0.718 |
| 7 | Repotrectinib | 34.3% | 65.7% | 84.21 | 0.608 |
| 8 | Neratinib | 33.6% | 66.4% | 93.18 | 0.597 |
| 9 | Pazopanib | 30.2% | 69.8% | 97.49 | 0.672 |
| 10 | Defactinib | 27.0% | 73.0% | 92.68 | 0.450 |
| 11 | Pralsetinib | 26.1% | 73.9% | 93.43 | 0.643 |
| 12 | Fedratinib | 25.5% | 74.5% | 96.21 | 0.576 |
| 13 | Netarsudil | 18.6% | 81.4% | 93.22 | 0.676 |
| 14 | Vemurafenib | 17.8% | 82.2% | 96.49 | 0.598 |
| 15 | Alpelisib | 16.3% | 83.7% | 97.22 | 0.720 |
| 16 | Abrocitinib | 15.5% | 84.5% | 99.50 | 0.581 |
| 17 | Midostaurin | 12.3% | 87.7% | 78.64 | 0.500 |
| 18 | Palbociclib | 11.4% | 88.6% | 98.75 | 0.673 |
| 19 | Ruxolitinib | 10.5% | 89.5% | 98.25 | 0.592 |
| 20 | Crizotinib | 9.9% | 90.1% | 91.39 | 0.581 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.17
- Epithelial log2(TPM+1): 0.58
- Fold change: -0.41
- Status: No significant change
High-confidence drugs
- Avapritinib — inh 89.7% · KISS 38.25
- Fostamatinib — inh 52.8% · KISS -8.33
- Ponatinib — inh 56.0% · KISS -13.34
Selectivity landscape vs inhibition on NEK5
Each point is one of the 92 approved drugs; color = inhibition % on NEK5.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…